Protective efficacy of an inactivated bivalent swine influenza vaccine

Swine influenza virus (SIV) is an important pathogen. Vaccination is the most effective way to prevent the disease. The objective of this study was to evaluate the protective efficacy of a commercial inactivated bivalent swine influenza vaccine (H1N1/H3N2). Vaccinated pigs with the three batches (# 201604, #201605, and #201606) had no clinical signs of disease, no viral shedding, and any lung lesions after the wild-type SIV-H1N1 LN and SIV-H3N2 HLJ challenge, and the unvaccinated pigs showed clinical signs of disease, had viral shedding, and severe lung lesions. Our results clearly demonstrate that three batches of vaccine products provided complete protection against the wild-type SIV-H1N1 LN and SIV-H3N2 HLJ challenge.